by Gil Porat, M.D., FACP, CPT
Intended for the medical professional who enjoys learning for the sake of it. Dr. Porat is a practicing Colorado Hospitalist and Board Certified in Internal Medicine.
Language
🇺🇲
Publishing Since
7/2/2012
Email Addresses
0 available
Phone Numbers
0 available
January 27, 2022
<p>The double-blind, randomized phase III EMPEROR-Preserved trial showed a benefit of the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF).</p> <p>Now let us dig a bit more into those headlines.</p> <p></p> <p> </p>
October 18, 2021
<p>An important recently published randomized control trial provides guidance on this controversy.</p>
June 27, 2021
The Curbsiders Internal Medicine Podcast
The Clinical Problem Solvers
Thomas Watchman
NEJM Group
Jed Wolpaw
CREOGs Over Coffee
Orthobullets
Australian Prescriber
Dr. Paul Kilgore, M.D.
Steve Matthes
Raj Dasgupta & MedPrepToGo
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.